Forte Biosciences reported that FB102 produced statistically significant improvement in a small placebo-controlled vitiligo study. CEO Paul Wagner emphasized that results continued to improve even after patients stopped treatment, suggesting a potentially durable effect. The update is a positive clinical-development signal, though the study size appears limited.
Forte Biosciences reported that FB102 produced statistically significant improvement in a small placebo-controlled vitiligo study. CEO Paul Wagner emphasized that results continued to improve even after patients stopped treatment, suggesting a potentially durable effect. The update is a positive clinical-development signal, though the study size appears limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
